tbuckley/cabot-search huggingface dataset:
Cardiopulmonary resuscitation for sudden cardiac arrest on the field of play: improving our standard!
Authors: João João Mendes, Paulo Beckert
Journal: British Journal of Sports Medicine (2021)

Sudden cardiac arrest (SCA) on the field of play (FoP) is a life-threatening event which requires a prompt and coordinated medical response.1 Guidelines for implementation of an emergency medical plan (EMP) for SCA have been previously outlined by the FIFA2 and UEFA,3 but the best available evidence to respond to the unique circumstances of the football athlete with SCA on the FoP continues to evolve.

Prompt recognition of SCA is the first step in an efficient EMP (figure 1). SCA should be considered in any player who presents with a non-contact collapse, recognising that brief myoclonic seizure-like activity (eg, shaking, quivering or twitching) may follow collapse and that continued chest and abdominal movements or gasps may be mistaken for normal breathing.2



Figure 1 
Emergency medical plan for SCA on the field of play. ACD, automatic chest compression device; CPR, cardiopulmonary resuscitation; eCPR, extracorporeal cardiopulmonary resuscitation; LMA, laryngeal mask airway; SCA, sudden cardiac arrest; ROSC, return of spontaneous circulation; TT, tracheal …
Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma.
Authors: Cassandra J Vandenberg, Gwo-Yaw Ho, Ksenija Nesic, Elizabeth M Swisher, Sean M Grimmond, Matthew J Wakefield, Holly E Barker, David D Bowtell, Clare L Scott
Journal: Cancer Research (2021)
CRISPR-derived genome editing therapies: Progress from bench to bedside
Authors: Holly A. Rees, Alex C. Minella, Cameron A. Burnett, Alexis C. Komor, Nicole M. Gaudelli
Journal: Molecular Therapy (2021)

The development of CRISPR-derived genome editing technologies has enabled the precise manipulation of DNA sequences within the human genome. In this review, we discuss the initial development and cellular mechanism of action of CRISPR nucleases and DNA base editors. We then describe factors that must be taken into consideration when developing these tools into therapeutic agents, including the potential for unintended and off-target edits when using these genome editing tools, and methods to characterize these types of edits. We finish by considering specific challenges associated with bringing a CRISPR-based therapy to the clinic, including manufacturing, regulatory oversight, and considerations for clinical trials that involve genome editing agents. The development of CRISPR-derived genome editing technologies has enabled the precise manipulation of DNA sequences within the human genome. In this review, we discuss the initial development and cellular mechanism of action of CRISPR nucleases and DNA base editors. We then describe factors that must be taken into consideration when developing these tools into therapeutic agents, including the potential for unintended and off-target edits when using these genome editing tools, and methods to characterize these types of edits. We finish by considering specific challenges associated with bringing a CRISPR-based therapy to the clinic, including manufacturing, regulatory oversight, and considerations for clinical trials that involve genome editing agents.
279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
Authors: C. Saura Manich, S. Modi, I. Krop, Y.H. Park, S-B. Kim, K. Tamura, F. André, H. Iwata, Y. Ito, J. Tsurutani, J. Sohn, C. Lee, Y. Liu, J. Cathcart, J. Singh, T. Yamashita
Journal: Annals of Oncology (2021)
738P Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial
Authors: M-P. Barretina-Ginesta, B.J. Monk, S. Han, B. Pothuri, A. Auranen, D. Chase, D. Lorusso, C. Anderson, S. Abadie-Lacourtoisie, N. Cloven, E.I. Braicu, A. Amit, A. Redondo, R. Shah, N. Kebede, C. Hawkes, D. Gupta, T. Woodward, D.M. O'Malley, A.J. Gonzalez Martin
Journal: Annals of Oncology (2021)
1670MO Validation of a new risk-assessment model for prediction of venous thromboembolism in cancer outpatients: The ONKOTEV score
Authors: C.A. Cella, M. Knoedler, M. Hall, S. Pellicori, L. Gervaso, R. Schorling, V. Bagnardi, F. Lordick, N. Fazio
Journal: Annals of Oncology (2021)
906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
Authors: A.R. Hansen, C.A. Gomez-Roca, M.P. Lolkema, L. Verlingue, A. Italiano, J. Spicer, N. Steeghs, J.E. Bauman, J. Fayette, J. Niu, H. Prenen, D. Dejardin, C. Boetsch, A. Kraxner, S. Evers, T. Vardar, N. Keshelava, V. Teichgräber, M. Bonomi
Journal: Annals of Oncology (2021)
From scientific research to helping your patient
Authors: Sietske van Berkel
Journal: British Journal of Sports Medicine (2021)

Evidence-based practice is the cornerstone of our clinical work and evidence-based guidelines are a key part of this. Dutch scientific associations, like our own Dutch Sports Medicine Association (VSG), are making advances in developing monodisciplinary and multidisciplinary guidelines. Developing and implementing these guidelines is supported by the Dutch Knowledge Institute of Medical Specialists. All scientific associations use state-of-the-art guideline development methods. The process is almost identical to the National Institute of Health and Care Excellence guideline process in the UK. Guidelines go further than just systematic literature reviews with a clear distinction between evidence and clinical considerations, and also include patients during the whole process.

Patient involvement is novel as it is often not included in standard systematic reviews. Yet, it is patients who have problems, not the doctor or physiotherapist who treats them. The patient’s opinion should matter and it is good to see that BJSM has room for the patient’s voice as can be read in the article by Rodriguez in this edition (see page 1179) . …
Oxytocin as an allostatic agent in the social bonding effects of music
Authors: Niels Chr. Hansen, Peter E. Keller
Journal: Behavioral and Brain Sciences (2021)

Abstract Despite acknowledging that musicality evolved to serve multiple adaptive functions in human evolution, Savage et al. promote social bonding to an overarching super-function. Yet, no unifying neurobiological framework is offered. We propose that oxytocin constitutes a socio-allostatic agent whose modulation of sensing, learning, prediction, and behavioral responses with reference to the physical and social environment facilitates music's social bonding effects.
459P Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment: Interim analysis of DISTINCTIVE trial
Authors: E. Lai, S. Lonardi, P. Ziranu, A. Cappetta, S. Cherri, C. Madeddu, S. Murgioni, S. Mosconi, V. Smiroldo, M. Squadroni, G. Barsotti, L. Mascia, G. Rosati, M.G. Zampino, F. Gelsomino, V. Conca, M.A. Palladino, C. Morelli, R. Bollina, M. Scartozzi
Journal: Annals of Oncology (2021)
Toward inclusive theories of the evolution of musicality
Authors: Patrick E. Savage, Psyche Loui, Bronwyn Tarr, Adena Schachner, Luke Glowacki, Steven Mithen, W. Tecumseh Fitch
Journal: Behavioral and Brain Sciences (2021)

Abstract We compare and contrast the 60 commentaries by 109 authors on the pair of target articles by Mehr et al. and ourselves. The commentators largely reject Mehr et al.'s fundamental definition of music and their attempts to refute (1) our social bonding hypothesis, (2) byproduct hypotheses, and (3) sexual selection hypotheses for the evolution of musicality. Instead, the commentators generally support our more inclusive proposal that social bonding and credible signaling mechanisms complement one another in explaining cooperation within and competition between groups in a coevolutionary framework (albeit with some confusion regarding terminologies such as “byproduct” and “exaptation”). We discuss the proposed criticisms and extensions, with a focus on moving beyond adaptation/byproduct dichotomies and toward testing of cross-species, cross-cultural, and other empirical predictions.
Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response
Authors: Kevin C. Johnson, Kevin J. Anderson, Elise T. Courtois, Amit D. Gujar, Floris P. Barthel, Frederick S. Varn, Diane Luo, Martine Seignon, Eunhee Yi, Hoon Kim, Marcos R. H. Estecio, Dacheng Zhao, Ming Tang, Nicholas E. Navin, Rahul Maurya, Chew Yee Ngan, Niels Verburg, Philip C. de Witt Hamer, Ketan Bulsara, Michael L. Samuels, Sunit Das, Paul Robson, Roel G. W. Verhaak
Journal: Nature Genetics (2021)
Regulatory drug approval: protecting patients or serving impatient shareholders?
Authors: Alain Braillon, Aubrey Blumsohn
Journal: BMJ (2021)

Gyawali and colleagues showed that a third of anticancer drugs approved by the US Food and Drug Administration on the basis of surrogate measures under accelerated processes remained authorised despite negative results after marketing authorisation.1

Regulatory agencies face a serious challenge, having only two speeds: too slow or too fast. However, the accumulating evidence indicates that they …
A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study
Authors: Pierre Fillâtre, Marie-José Dufour, Sylvie Behillil, Rémi Vatan, Pascale Reusse, Alice Gabellec, Nicolas Velmans, Catherine Montagne, Sophie Geffroy Du Coudret, Edith Droumaguet, Véronique Merour, Vincent Enouf, Rodolphe Buzelé, Marion Valence, Elena Guillotel, Bertrand Gagnière, Artem Baidaliuk, Anna Zhukova, Mathieu Tourdjman, Vincent Thibault, Claire Grolhier, Charlotte Pronier, François-Xavier Lescure, Etienne Simon-Loriere, Dominique Costagliola, Sylvie Van Der Werf, Pierre Tattevin, Nicolas Massart
Journal: Clinical Microbiology and Infection (2021)

ObjectivesIn early January 2021 an outbreak of nosocomial cases of coronavirus disease 2019 (COVID-19) emerged in Western France; RT-PCR tests were repeatedly negative on nasopharyngeal samples but positive on lower respiratory tract samples. Whole-genome sequencing (WGS) revealed a new variant, currently defining a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage B.1.616. In March, the WHO classified this as a 'variant under investigation' (VUI). We analysed the characteristics and outcomes of COVID-19 cases related to this new variant.MethodsClinical, virological, and radiological data were retrospectively collected from medical charts in the two hospitals involved. We enrolled those inpatients with: (a) positive SARS-CoV-2 RT-PCR on a respiratory sample, (b) seroconversion with anti-SARS-CoV-2 IgG/IgM, or (c) suggestive symptoms and typical features of COVID-19 on a chest CT scan. Cases were categorized as B.1.616, a variant of concern (VOC), or unknown.ResultsFrom 1st January to 24th March 2021, 114 patients fulfilled the inclusion criteria: B.1.616 (n = 39), VOC (n = 32), and unknown (n = 43). B.1.616-related cases were older than VOC-related cases (81 years, interquartile range (IQR) 73–88 versus 73 years, IQR 67–82, p < 0.05) and their first RT-PCR tests were rarely positive (6/39, 15% versus 31/32, 97%, p < 0.05). The B.1.616 variant was independently associated with severe disease (multivariable Cox model HR 4.0, 95%CI 1.5–10.9) and increased lethality (28-day mortality 18/39 (46%) for B.1.616 versus 5/32 (16%) for VOC, p = 0.006).ConclusionWe report a nosocomial outbreak of COVID-19 cases related to a new variant, B.1.616, which is poorly detected by RT-PCR on nasopharyngeal samples and is associated with high lethality.Graphical abstract
1554TiP A randomized phase II study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced or metastatic soft tissue sarcoma
Authors: T. Kessler, D. Pink, P. Reichardt, E. Palmerini, S. Stacchiotti, G. Grignani, P. Rutkowski, T. Hemmerle, D. Neri, C. Schliemann
Journal: Annals of Oncology (2021)
Abstract 14572: Cardiac I-123 Metaiodobenzylguanidine Imaging Could Identify Patients With Chronic Heart Failure and LVEF<35% at Low Risk for Cardiac Death, Irrespective of Mode of Death
Authors: Tsutomu Kawai, Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Yusuke Iwasaki, Masato Kawasaki, Astushi Kukuchi, Kentaro Ozu, Takumi Kondo, Kaoruko Sengoku, Hironori Yamamoto, Satosho Takahashi, Msashi Ishimi, Hideyuki Hakui, Masatake Fukunami
Journal: Circulation (2013)

Background: Prediction of mode of death (sudden cardiac death (SCD) and pump failure death (PFD)) in patients with chronic heart failure (CHF) may facilitate decisions about specific medications or...
278P Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients
Authors: S. Krasny, S. Polyakov, E. Zhavrid, A. Khorau, Y. Baranau, S. Kozlovskaya, O. Sergeeva, K. Zharkova, A.A. Sufianov, V. Gabai, A. Shneider
Journal: Annals of Oncology (2021)
699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
Authors: J.E. Rosenberg, M.D. Galsky, A.V. Balar, Y. Loriot, A. Necchi, J. Hoffman-Censits, S. Srinivas, A. Drakaki, A. Javery, B. Nelson, H.X. Huang, X. Shen, M.S. van der Heijden
Journal: Annals of Oncology (2021)
1430P Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK
Authors: C. Kopp, S. Lorenzen, T. Gaiser, P.C. Thuss-Patience, M. Schenk, U. Lindig, A. Kretzschmar, V. Heuer, E. Goekkurt, G.M. Haag, J. Riera Knorrenschild, C. Bolling, R.D. Hofheinz, A.R. Siebenhuener, N. Irahara, L. Waberer, C. Pauligk, T.O. Götze, N. Homann, S-E. Al-Batran
Journal: Annals of Oncology (2021)
Solitary Hepatic Metastasis From Papillary Thyroid Carcinoma
Authors: Xiaoxia Wen, Haixia Yin, Deshan Zhao
Journal: Clinical Nuclear Medicine (2021)

Papillary thyroid carcinoma commonly metastasizes to regional lymph nodes. However, metastasis to liver alone is extremely rare. Here we present a 36-year-old woman who underwent total thyroidectomy and bilateral neck lymph nodes dissection for papillary thyroid carcinoma and received radioiodine (131I) ablation therapy for 2 times 1 month and 5 months after surgery, respectively. The images after the 131I therapy showed a solitary occult metastasis in the liver.
Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*
Authors: L. Frumholtz, J.‐D. Bouaziz, M. Battistella, J. Hadjadj, R. Chocron, D. Bengoufa, H. Le Buanec, L. Barnabei, S. Meynier, O. Schwartz, L. Grzelak, N. Smith, B. Charbit, D. Duffy, N. Yatim, A. Calugareanu, A. Philippe, C.L. Guerin, B. Joly, V. Siguret, L. Jaume, H. Bachelez, M. Bagot, F. Rieux‐Laucat, S. Maylin, J. Legoff, C. Delaugerre, N. Gendron, D.M. Smadja, C. Cassius
Journal: British Journal of Dermatology (2021)

BackgroundThe outbreak of chilblain‐like lesions (CLL) during the COVID‐19 pandemic has been reported extensively, potentially related to SARS‐CoV‐2 infection, yet its underlying pathophysiology is unclear.
1549P Pazopanib exposure in advanced soft tissue and bone sarcoma: A pharmacokinetic/pharmacodynamic analysis
Authors: M-S. Minot, P. Boudou Rouquette, A. Jouinot, D. Balakirouchenane, C. Tlemsani, S. De Percin, J. Chen, M. Tiako Meyo, A. Thomas-Schoemann, F. Goldwasser, B. Blanchet, J. Alexandre
Journal: Annals of Oncology (2021)
Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies
Authors: Janice M. Bonsu, Onaopepo Kola-Kehinde, Lisa Kim, Patrick Ruz, Courtney M. Campbell, Jonathan E. Brammer, Daniel Addison
Journal: JAMA Oncology (2021)

This cohort study examines the prevalence and factors associated with postmarketing communications by the US Food and Drug Administration about cardiovascular events associated with anticancer thearpy.
911P Case series of docetaxel, trastuzumab, and pertuzumab (DTP) and subsequent ado-trastuzumab emtansine (T-DM1) for recurrent or metastatic (R/M) HER2-positive salivary duct carcinoma (SDC)
Authors: M. Uijen, G. Lassche, A. van Engen-van Grunsven, C. Driessen, C.M.L. Van Herpen
Journal: Annals of Oncology (2021)
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Authors: Carla Casulo, Jesse G. Dixon, Jennifer Le-Rademacher, Eva Hoster, Howard S. Hochster, Wolfgang Hiddemann, Robert Marcus, Eva Kimby, Michael Herold, Catherine Sebban, Emmanuel Gyan, Kenneth Foon, Tina Nielsen, Umberto Vitolo, Gilles A. Salles, Qian Shi, Christopher R. Flowers
Journal: Blood (2022)
1680P Feasibility of home-based supervised physical activity (SPA) for metastatic cancer patients receiving oral targeted therapy: The AFSOS-Unicancer QUALIOR randomized phase II study
Authors: F. Joly Lobbedez, C. Lefeuvre-Plesse, E. Charton, C. Helissey, F. Priou, L. Stefani, V. Simmet, C. Garnier-Tixidre, N. Meneveau, N. Houede, S. Salas, E. Bourbouloux, J-M. Descotes, A. Anota, S. Nenan, I. Rieger
Journal: Annals of Oncology (2021)
1701P Impact of the CARG score and treatment intensity on survival and toxicity outcomes in older adults with non-colorectal gastrointestinal (GI) cancers
Authors: T.F. Nishijima, A.M. Deal, C.K. Osterman, T. Brenizer, G.R. Williams, H.K. Sanoff, K.A. Nyrop, H.B. Muss
Journal: Annals of Oncology (2021)
1705P The correlation of the ECOG performance status with vulnerabilities in the geriatric assessment: A retrospective cohort study
Authors: S. Gattani, V. Noronha, R. Castelino, R. Dhekle, S. Mahajan, A. Daptardar, N.S. Menon, V.M. Patil, V. Gota, S. Banavali, K. Prabhash
Journal: Annals of Oncology (2021)
Sixty seconds on . . . #IAmNotYourVillain
Authors: Rebecca Coombes
Journal: BMJ (2021)

The charity Changing Faces has called on 007 producers to feature a positive character with a visible difference in the next film. No Time to Die has been branded as tired, lazy, and archaic for featuring villains with scarring. The charity’s #IAmNotYourVillain campaign has released its own short film of people with disfigurements playing screen idols such as Audrey Hepburn, Black Panther, and Indiana Jones.

Absolutely. Curiously, Ian Fleming’s Bond was originally …
1472P Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study
Authors: C. Evrard, P. Ingrand, G. Tachon, N. Flores, T. Rochelle, M. Martel, V. Randrian, A. Ferru, P-A. Haineaux, N. Isambert, L. Karayan Tapon, D. Tougeron
Journal: Annals of Oncology (2021)
1328P Outcomes from local consolidative therapy and immune checkpoint inhibitors in metastatic non-small cell lung cancer
Authors: L. Hong, W. Rinsurongkawong, V. Rinsurongkawong, A.R. Spelman, J. Lewis, S.J. Gandhi, M.B. Antonoff, D.L. Gibbons, A.A. Vaporciyan, J.J. Lee, J.V. Heymach, J. Zhang, N.I. Vokes
Journal: Annals of Oncology (2021)
1780P Clinical utility of the ESMO Precision Medicine Working Group recommendation on indication for germline follow-up testing in tumour-only sequencing
Authors: T. Kondo, M. Kanai, Y. Yamamoto, K. Fukuyama, J. Matsubara, Q. Pham Nguyen, M. Yoshioka, T. Yamada, S. Kosugi, M. Muto
Journal: Annals of Oncology (2021)
1391P Clinical progress in inoperable or recurrent advanced gastric cancer treatment from 1,004 single institute experiences between 2007 and 2018
Authors: I. Nakayama, D. Takahari, K. Shimozaki, K. Chin, T. Wakatsuki, A. Oki, D. Kamiimabeppu, H. Osumi, M. Ogura, E. Shinozaki, K. Yamaguchi
Journal: Annals of Oncology (2021)
1305P Peripheral low-density neutrophils in the response to immunotherapy in untreated non-small cell lung cancer
Authors: H. Arasanz, A.I. Bocanegra Gondan, E.B. Palmeiro, M. Zuazo, I. Morilla Ruiz, M. Martínez-Aguillo, L. Teijeira, G. Fernández-Hinojal, L. Chocarro, P. Morente Sancho, D. Escors, R. Vera, G. Kochan
Journal: Annals of Oncology (2021)
505TiP REGINA: A phase II trial of neoadjuvant regorafenib (rego) in combination with nivolumab (nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC)
Authors: G. Bregni, C. Senti, E. Acedo Reina, P. Gkolfakis, L. Moretti, A. Veron, P. Demetter, G. Liberale, J. Carrasco, K. Geboes, Y. Gokburun, M. Peeters, M. Van den Eynde, J-L. van Laethem, P. Vergauwe, M.E. Buyse, A. Deleporte, A. Hendlisz, F. Sclafani
Journal: Annals of Oncology (2021)
Loss of proximal tubular transcription factor Krüppel-like factor 15 exacerbates kidney injury through loss of fatty acid oxidation
Authors: Sian E. Piret, Ahmed A. Attallah, Xiangchen Gu, Yiqing Guo, Nehaben A. Gujarati, Justina Henein, Amy Zollman, Takashi Hato, Avi Ma’ayan, Monica P. Revelo, Kathleen G. Dickman, Chung-Hsin Chen, Chia-Tung Shun, Thomas A. Rosenquist, John C. He, Sandeep K. Mallipattu
Journal: Kidney International (2021)
379TiP TEM-GBM: A phase I-IIa clinical study of genetically modified Tie-2-expressing monocytes in patients with glioblastoma multiforme
Authors: G. Finocchiaro, B. Gentner, M. Eoli, A. Capotondo, F. Farina, E. Anghileri, M.G. Carrabba, V. Cuccarini, F. Di Meco, F. Legnani, B. Pollo, M. Saini, P. Ferroli, R. Pallini, S. Mazzoleni, M.G. Bruzzone, A. Olivi, C. Russo, L. Naldini, F. Ciceri
Journal: Annals of Oncology (2021)